Literature DB >> 16527606

Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization.

German G Gomez1, Marileila Varella-Garcia, Carol A Kruse.   

Abstract

Intratumoral heterogeneity and genetic instability within gliomas may allow intrinsically immunoresistant (IR) cells to escape alloreactive cytotoxic T lymphocyte (aCTL) cellular immunotherapy. The potential existence of aCTL-resistant variants prompted us to investigate whether cellular immunotherapy resistant glioma models could be isolated. To generate the models, repeated intermittent or continuous selective pressure (ISP or CSP) with multiple aCTL populations was applied to a low-passage glioblastoma cell explant, 13-06-MG, obtained from a patient at initial diagnosis. IL-6 and IL-8 secretion was greater in coincubates of aCTL cells with 13-06-ISP and 13-06-CSP immunoselected cells than those with 13-06-MG parental cells. Initially, the immunoselected cells were less sensitive to aCTL lysis; however, the reduced aCTL-sensitivity was not maintained upon further selection. We therefore isolated IR clones from continuously immunoselected cells (13-06-CSP). The frequency of IR clones was 1-6 cells per 10,000 immunoselected cells. Two clones selected for further study, 13-06-IR29 and 13-06-IR30, resisted aCTL lysis in the absence of immunoselective pressure. Cytogenetic analyses revealed structural anomalies and genomic imbalances unique to the IR clones. Based on these findings, a hypothetical model is proposed that traces the origin of the IR clones to a clonal variant within the 13-06-CSP and 13-06-MG populations.

Entities:  

Mesh:

Year:  2006        PMID: 16527606      PMCID: PMC1447520          DOI: 10.1016/j.cancergencyto.2005.08.009

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  39 in total

1.  Isolation and culture of human brain tumor cells.

Authors:  German G Gomez; Carol A Kruse
Journal:  Methods Mol Med       Date:  2004

2.  A direct comparison of procedures for the detection of mycoplasma in tissue culture.

Authors:  J J Hessling; S E Miller; N L Levy
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

Review 3.  Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy.

Authors:  Francisco Ruiz-Cabello; Teresa Cabrera; Miguel-Angel Lopez-Nevot; Federico Garrido
Journal:  Semin Cancer Biol       Date:  2002-02       Impact factor: 15.707

4.  Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.

Authors:  Steven A Rosenberg; James C Yang; Paul F Robbins; John R Wunderlich; Patrick Hwu; Richard M Sherry; Douglas J Schwartzentruber; Suzanne L Topalian; Nicholas P Restifo; Armando Filie; Richard Chang; Mark E Dudley
Journal:  J Immunother       Date:  2003 Sep-Oct       Impact factor: 4.456

5.  Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines.

Authors:  Adrie van Bokhoven; Aimee Caires; Michael Di Maria; Aline Passarini Schulte; M Scott Lucia; Steven K Nordeen; Gary J Miller; Marileila Varella-Garcia
Journal:  Prostate       Date:  2003-11-01       Impact factor: 4.104

6.  Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling.

Authors:  Pachiyappan Kamarajan; Nian-Kang Sun; Chuck C-K Chao
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

7.  Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity.

Authors:  Emilio Fiore; Carlo Fusco; Pedro Romero; Ivan Stamenkovic
Journal:  Oncogene       Date:  2002-08-08       Impact factor: 9.867

8.  Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

Authors:  German G Gomez; Susana B Read; Lazaro E Gerschenson; Daniela Santoli; Adam Zweifach; Carol A Kruse
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

9.  Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.

Authors:  Pinku Mukherjee; Cathy S Madsen; Amelia R Ginardi; Teresa L Tinder; Fred Jacobs; Joanne Parker; Babita Agrawal; B Michael Longenecker; Sandra J Gendler
Journal:  J Immunother       Date:  2003 Jan-Feb       Impact factor: 4.456

10.  Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma.

Authors:  Akihide Fujimoto; Hiroya Takeuchi; Bret Taback; Eddy C Hsueh; David Elashoff; Donald L Morton; Dave S B Hoon
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

View more
  7 in total

Review 1.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Authors:  F M Hofman; A Stathopoulos; C A Kruse; T C Chen; V E J C Schijns
Journal:  Anticancer Agents Med Chem       Date:  2010-07       Impact factor: 2.505

2.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

3.  Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas.

Authors:  Michelle J Hickey; Colin C Malone; Kate E Erickson; German G Gomez; Emma L Young; Linda M Liau; Robert M Prins; Carol A Kruse
Journal:  Am J Transl Res       Date:  2012-01-10       Impact factor: 4.060

4.  Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.

Authors:  Richard G Everson; Joseph P Antonios; Dominique N Lisiero; Horacio Soto; Rudi Scharnweber; Matthew C Garrett; William H Yong; Ning Li; Gang Li; Carol A Kruse; Linda M Liau; Robert M Prins
Journal:  Neuro Oncol       Date:  2015-09-01       Impact factor: 12.300

Review 5.  Transforming growth factor-beta and its implication in the malignancy of gliomas.

Authors:  Laurent-Olivier Roy; Marie-Belle Poirier; David Fortin
Journal:  Target Oncol       Date:  2014-03-05       Impact factor: 4.493

6.  Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors.

Authors:  German G Gomez; Michelle J Hickey; Richard Tritz; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2008-06

7.  Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.

Authors:  German G Gomez; Carol A Kruse
Journal:  J Immunother       Date:  2007-04       Impact factor: 4.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.